FDA – Page 309 – Pharma.Tips

Unplanned Line Stoppage during hold-time study: risk assessment for patient safety and recall

Risk Assessment for Patient Safety Following Unplanned Line Stoppage during a Hold-Time Study In pharmaceutical manufacturing, an unplanned line stoppage during a hold-time study can pose significant risks to product…

Aseptic Gowning Deviation after maintenance intervention: risk assessment for patient safety and recall

Aseptic Gowning Deviation Investigation Post-Maintenance Intervention: Ensuring Compliance and Patient Safety Aseptic processing is pivotal in pharmaceutical manufacturing, particularly for parenteral dosage forms. When deviations occur—such as an aseptic gowning…

Odor Change during method transfer: mixing and sampling controls for QA review

Investigating Odor Changes during Method Transfers: Effective Controls for Quality Assurance Review Odor changes during method transfers can signal underlying issues that compromise product quality and regulatory compliance. This article…

Em Excursion In Grade A during PAI readiness: facility, people, process root cause mapping

Identifying the Root Causes of Em Excursions in Grade A During PAI Readiness In the pharmaceutical manufacturing industry, maintaining compliance with strict standards is crucial, particularly in sterile manufacturing areas…

Bioburden Spike Pre-Filtration during routine EM trending: facility, people, process root cause mapping

Mapping the Root Causes of Bioburden Spikes in Pre-Filtration During Routine Environmental Monitoring Trending Bioburden spikes in pre-filtration during routine environmental monitoring (EM) present significant challenges for pharmaceutical manufacturers, particularly…

Texture Variability after excipient change: GMP investigation and CAPA strategy

GMP Investigation and CAPA Strategy for Texture Variability Following Excipient Changes In the dynamic environment of pharmaceutical manufacturing, excipients play a crucial role in determining the quality of dosage forms.…

Filter Integrity Failure during routine EM trending: how to classify deviation and set disposition

Addressing Filter Integrity Failures during Routine Environmental Monitoring: A Comprehensive Investigation Guide In the highly regulated environment of pharmaceutical manufacturing, the failure of filter integrity during routine environmental monitoring (EM)…

Particulate Matter Oos during routine EM trending: FDA/MHRA investigation narrative and batch impact

Understanding OOS Results for Particulate Matter in Environmental Monitoring Trends: A Structured Investigation Particulate matter (PM) unexpectedly flagged as out-of-specification (OOS) during routine environmental monitoring (EM) can cause significant concerns…

Air Entrapment in cream manufacturing: packaging compatibility and stability justification

Investigating Air Entrapment in Cream Manufacturing: Ensuring Packaging Compatibility and Stability In pharmaceutical cream manufacturing, air entrapment can lead to significant quality issues, impacting both packaging compatibility and product stability.…

Aseptic Gowning Deviation during terminal sterilization: risk assessment for patient safety and recall

Aseptic Gowning Deviation during Terminal Sterilization: Assessing Risk and Ensuring Compliance In the highly regulated world of pharmaceutical manufacturing, maintaining sterility is critical, particularly during terminal sterilization processes. An aseptic…

Unplanned Line Stoppage post-sterile filtration: facility, people, process root cause mapping

Root Cause Analysis of Unplanned Line Stoppage After Sterile Filtration The pharmaceutical industry often faces challenges that can result in unplanned line stoppages during critical processes such as sterile filtration.…

Air Entrapment during inspection preparation: GMP investigation and CAPA strategy

Addressing Air Entrapment Issues during Inspection Preparation in Pharmaceutical Manufacturing Air entrapment during inspection preparation can pose significant challenges in pharmaceutical manufacturing, particularly in the production of topical and dermatological…